Prospective, open-label study compared 19 Takayasu pts on secukinumab vs 34 pts on TNFi . SEC response (Complete/partial
Tweet Content
Prospective, open-label study compared 19 Takayasu pts on secukinumab vs 34 pts on TNFi . SEC response (Complete/partial) was 53% & the TNFi response was 59% at 3 mos. SEC had 4 pts relapse by wk 48 (median 31 wks(, TNFi had 12 pts relapse. https://t.co/IQDFDmbdBR https://t.co/hIx6qvzAO8
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off